Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax Technologies and AstraZeneca have announced to carry forward the advancement of AZD1419 into IND-enabling preclinical toxicology studies.
Subscribe to our email newsletter
AZD1419 is a second-generation TLR-9 agonist for asthma.
The cost of development will be fully funded by AstraZeneca, and Dynavax will receive payment of $2.6m to begin the studies as per the collaboration.
Preclinical studies have suggested that AZD1419 is capable of producing long lasting disease-modifying effects in a mouse model of atopic asthma.
Under the terms of the amended 2006 research collaboration and license agreement, AstraZeneca will provide around $20m in payments to Dynavax to cover the cost of clinical development activities through Phase 2a.